Stock Events

Stock Events

Capricor Therapeutics 

€7.82
109
+€0.27+3.6%Friday 16:30

Statistics

Day High
7.68
Day Low
7.68
52W High
7.94
52W Low
5.19
Volume
-
Avg. Volume
-
Mkt Cap
454.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 10Expected
Q2 2026
Next
-0.61
-0.45
-0.28
-0.12
Expected EPS
-0.1236419772
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-91.18MNet Income

Analyst Ratings

$18.72Average Price Target
The highest estimate is ⁦21.25⁩.
From 5 ratings within the last 6 months. This is not an investment recommendation.
Buy
60%
Hold
40%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4LN2.XETRA. It's not an investment recommendation.
NVIDIA
25
NVDA
Alphabet
20
GOOGL
Apple
19
AAPL
Amazon
19
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases, directly competing with Capricor's focus on cardioskeletal diseases and Duchenne muscular dystrophy.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.33B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including therapies for genetic diseases, competing in the same space as Capricor.
PTC Therapeutics
PTCT
Mkt Cap5.01B
PTC Therapeutics focuses on the development of orally administered small molecule drugs that regulate gene expression, including treatments for muscular dystrophy, overlapping with Capricor's therapeutic areas.
Solid Biosciences
SLDB
Mkt Cap664.8M
Solid Biosciences is dedicated to solving Duchenne muscular dystrophy (DMD) and other neuromuscular diseases, directly competing with Capricor's DMD programs.
Pfizer
PFE
Mkt Cap173.95B
Pfizer, a large pharmaceutical company, has a broad range of products including in areas that compete with Capricor's niche, such as cardiovascular and rare diseases treatments.
Moderna
MRNA
Mkt Cap88.52B
Moderna, known for its mRNA technology, is exploring treatments in areas that could compete with Capricor, especially in regenerative medicine and rare diseases.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline has a diverse portfolio that includes vaccines and treatments for a variety of diseases, some of which may compete with Capricor's therapeutic areas.
Novo Nordisk
NVO
Mkt Cap176.43B
Novo Nordisk focuses on diabetes care but also has interests in hemophilia and growth disorders, potentially competing with Capricor's cardioskeletal and rare disease treatments.

About

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Show More
CEO
Linda Marbán
Employees
231
Country
United States
ISIN
US14070B3096
WKN
000A2PLU4

Listings

STU
DE
4LN2.STU
F
DE
4LN2.F
STU
DE
4LN1.STU
XNAS
US
CAPR

0 Comments

Share your thoughts

FAQs

What is Capricor Therapeutics stock price today?▼
The current price of 4LN2.XETRA is €7.82 EUR — it has increased by +3.6% in the past 24 hours. Watch Capricor Therapeutics stock price performance more closely on the chart.
What is Capricor Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Capricor Therapeutics stocks are traded under the ticker 4LN2.XETRA.
What is Capricor Therapeutics market cap?▼
Today Capricor Therapeutics has the market capitalization of 454.53M
When is the next Capricor Therapeutics earnings date?▼
Capricor Therapeutics is going to release the next earnings report on November 10, 2026.
What were Capricor Therapeutics earnings last quarter?▼
4LN2.XETRA earnings for the last quarter are -0.61 EUR per share, whereas the estimation was -0.51 EUR resulting in a -18.87% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Capricor Therapeutics revenue for the last year?▼
Capricor Therapeutics revenue for the last year amounts to 0 EUR.
What is Capricor Therapeutics net income for the last year?▼
4LN2.XETRA net income for the last year is -91.18M EUR.
How many employees does Capricor Therapeutics have?▼
As of November 8, 2026, the company has 231 employees.
In which sector is Capricor Therapeutics located?▼
Capricor Therapeutics operates in the Health & Wellness sector.
When did Capricor Therapeutics complete a stock split?▼
The last stock split for Capricor Therapeutics was on June 5, 2019 with a ratio of 1:10.
Where is Capricor Therapeutics headquartered?▼
Capricor Therapeutics is headquartered in SAN DIEGO, United States.